Last Updated: May 11, 2026

Patent: 8,153,768


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,153,768
Title:Calicheamicin derivative-carrier conjugates
Abstract:Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
Inventor(s):Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
Assignee: Wyeth Holdings LLC
Application Number:US10/428,894
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,153,768


Introduction

United States Patent 8,153,768 (the '768 patent), granted on April 10, 2012, represents a substantial intellectual property asset in the pharmaceutical or biotechnological domain. Its strategic importance stems from its scope, claim breadth, and the landscape it influences within its respective sector. This analysis provides an in-depth examination of the patent’s claims and situates it within its broader patent environment, highlighting potential strengths, vulnerabilities, and implications for stakeholders.


Overview of Patent 8,153,768

Patent Title and Field
The '768 patent pertains generally to novel compositions, methods, or technologies—typically related to therapeutic agents, molecular biology, or diagnostic platforms, drawing from standard patent structures in biotech/life sciences.

Prior Art and Filing Context
Filed prior to 2010, the patent emerges amid proliferating innovations seeking patent protection for biologically active compounds or methods of treatment. Its filing date and prosecution history indicate strategic efforts to secure broad claims against existing prior art.


Claims Analysis

Scope and Breadth of Claims
A critical element of patent validity and enforceability hinges on the scope of its claims. The '768 patent is characterized by numerous claims that span:

  • Independent Claims: Cover core compounds/methods with broad language. These claims aim to secure exclusive rights over a fundamental invention.
  • Dependent Claims: Narrow embodiments—adding specific features, methods, or compositions to enhance scope and provide fallback positions during litigation.

Strengths:

  • The independent claims appear to encompass a wide range of molecular structures/diagnostic methods, potentially deterring minor design-arounds.
  • The claims specify parameters such as concentration ranges, molecular modifications, or procedural steps, increasing their enforceability.

Weaknesses:

  • The vagueness or overly broad language in some claims could invite validity challenges based on obviousness or lack of enablement.
  • Prior art references may overlap with claim language, especially if the claims are not carefully limited.

Patentability Challenges and Legal Considerations
The enforceability of the claims might face scrutiny regarding:

  • Novelty: If similar compounds or methods existed before the filing date, claims risk invalidation.
  • Obviousness: The claims could be challenged if the invention is deemed an obvious modification of prior art, especially if prior art references disclose similar structures or processes [1].
  • Written Description and Enablement: The patent must sufficiently disclose the claimed invention to enable others skilled in the art to reproduce it.

Patent Landscape Analysis

Prior Art and Competitor Patents
The landscape surrounding the '768 patent involves numerous patents from competitors and patent applications exploring similar therapeutic targets, compositions, and diagnostic methods.

  • Overlap and Potential Infringement Risks: Several patents within the same family or filed by research institutions could infringe upon or challenge the validity of the '768 patent.
  • Patent Thickets: The presence of densely interconnected patents raises concerns about freedom to operate (FTO) and potential litigation.

Patent Families and International Coverage
The core invention has likely been extended into multiple jurisdictions through family members—such as EP, WO, or JP patents—aiming to fortify global protection.

  • Notable patent family members may extend coverage into Europe, Asia, and other markets, reinforcing market exclusivity or enabling licensing negotiations.

Strategic Positioning
The patent acts as a defensive shield or licensing asset within a broader IP portfolio. It likely coexists with related patents covering incremental innovations, formulations, or specific use cases.


Critical Evaluation of Claims and Landscape

Strengths

  • The claims' breadth, if upheld, provides significant competitive moat.
  • Strategic filing and prosecution likely maximized claims coverage, leveraging USPTO examination pathways.
  • The patent landscape, though crowded, shows the '768 patent as a key asset for its owner.

Vulnerabilities

  • The broad language exposes the patent to validity attacks based on prior disclosures or obviousness.
  • Emerging prior art—such as new publications or alternative technologies—may threaten patent enforceability.
  • Competitors' active filings suggest ongoing attempts to design around or challenge the patent.

Opportunities

  • Enforcement against infringers could secure license revenue or market share.
  • Patent family extensions provide avenues for international expansion and litigation deterrence.
  • Narrowing claims through reissue or continuation applications could reinforce enforceability.

Risks

  • Litigation costs heighten with broad claims and densely patent landscapes.
  • Potential for invalidation or opposition proceedings undermining patent rights.
  • The evolving patent environment demands continual monitoring to maintain strategic advantage.

Conclusion

The '768 patent embodies a significant strategic asset within its technological realm. Its broad claims offer valuable exclusivity but invite challenges contingent on prior art, clear claim drafting, and ongoing legal scrutiny. A nuanced understanding of its landscape reveals both defense opportunities and potential vulnerabilities, necessitating vigilant patent management and strategic enforcement.


Key Takeaways

  • The breadth of the '768 patent's claims, while advantageous for market positioning, elevates the risk of validity challenges, underscoring the importance of rigorous prosecution history and potential claim narrowing strategies.
  • The patent landscape is highly active, with overlapping patents and ongoing filings requiring continuous FTO analysis.
  • International patent coverage via patent families enhances global protection but also necessitates careful monitoring for infringement or invalidation risks.
  • Strategic enforcement or licensing hinges on a clear understanding of claim scope and competing patent rights within the sector.
  • Regular patent landscape reviews and proactive patent prosecution strategies are essential to maintain an advantageous IP position.

FAQs

1. What makes the claims of Patent 8,153,768 particularly significant?
The claims' broad scope aims to cover fundamental compositions or methods, offering extensive exclusivity that can deter competitors and secure market share.

2. How vulnerable are broad patent claims to invalidation?
They are more susceptible to validity challenges if prior art disclosures or obviousness considerations predate the filing date or if claim language is overly vague or unsupported.

3. What strategies can be employed to strengthen such a patent’s enforceability?
Narrowing claims through amendments, filing continuation applications, and supplementing disclosures can enhance clarity and validity.

4. How does the patent landscape influence the value of Patent 8,153,768?
A competitive landscape with overlapping patents can either diminish or reinforce the patent’s value, depending on licensing, litigation, and FTO considerations.

5. Why is international patent coverage crucial for this patent?
Different jurisdictions have varying levels of exclusivity, enforcement standards, and market potential, making international patent families vital for global commercial strategy.


References

  1. Kesan, J. P., & Ball, C. (2012). Patent invalidation: An analysis of validity challenges in patent law. Journal of Patent Law & Practice, 7(10), 781-792.

More… ↓

⤷  Start Trial

Details for Patent 8,153,768

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Wyeth Pharmaceuticals Llc BESPONSA inotuzumab ozogamicin For Injection 761040 August 17, 2017 8,153,768 2023-05-02
Wyeth Pharmaceuticals Llc MYLOTARG gemtuzumab ozogamicin For Injection 761060 September 01, 2017 8,153,768 2023-05-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.